REDWOOD CITY, Calif. & BOSTON / Oct 04, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.
Details of the poster presentation is as follows:
Abstract Title: Characterization of Allogeneic CAR γδ1 T Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope on PSMA (Prostate-Specific Membrane Antigen)
Poster Number: C117
Presenting Author: Nitya Ramadoss, PhD
Date/Time: Saturday, October 14, from 12:30 p.m. - 4:00 p.m. PDT
Session Location: Level 2, Exhibit Hall D
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
Last Trade: | US$0.75 |
Daily Change: | 0.0025 0.33 |
Daily Volume: | 199,290 |
Market Cap: | US$61.960M |
March 06, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load